Pulmatrix (PULM) Revenue & Revenue Breakdown
Pulmatrix Revenue Highlights
Latest Revenue (Y)
$7.30M
Latest Revenue (Q)
$366.00K
Main Segment (Y)
Toxicology Study Costs
Main Geography (Y)
Toxicology Study Costs
Pulmatrix Revenue by Period
Pulmatrix Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $7.30M | 20.21% |
| 2022-12-31 | $6.07M | 17.45% |
| 2021-12-31 | $5.17M | -59.09% |
| 2020-12-31 | $12.63M | 59.72% |
| 2019-12-31 | $7.91M | 5069.93% |
| 2018-12-31 | $153.00K | -54.33% |
| 2017-12-31 | $335.00K | -59.88% |
| 2016-12-31 | $835.00K | -30.47% |
| 2015-12-31 | $1.20M | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-03-31 | - | - |
Pulmatrix generated $7.30M in revenue during NA 2023, up 20.21% compared to the previous quarter, and up 4769.93% compared to the same period a year ago.
Pulmatrix Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $366.00K | -76.42% |
| 2024-06-30 | $1.55M | -73.63% |
| 2024-03-31 | $5.88M | 167.26% |
| 2023-12-31 | $2.20M | 25.61% |
| 2023-09-30 | $1.75M | -4.93% |
| 2023-06-30 | $1.84M | 23.02% |
| 2023-03-31 | $1.50M | -12.24% |
| 2022-12-31 | $1.71M | -8.76% |
| 2022-09-30 | $1.87M | 40.65% |
| 2022-06-30 | $1.33M | 14.74% |
| 2022-03-31 | $1.16M | 154.39% |
| 2021-12-31 | $456.00K | -57.34% |
| 2021-09-30 | $1.07M | -52.57% |
| 2021-06-30 | $2.25M | 62.16% |
| 2021-03-31 | $1.39M | -30.50% |
| 2020-12-31 | $2.00M | -54.25% |
| 2020-09-30 | $4.37M | 24.91% |
| 2020-06-30 | $3.50M | 26.72% |
| 2020-03-31 | $2.76M | 63.92% |
| 2019-12-31 | $1.69M | 19.84% |
| 2019-09-30 | $1.41M | -70.82% |
| 2019-06-30 | $4.82M | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | -100.00% |
| 2018-03-31 | $153.00K | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2017-09-30 | $335.00K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $117.00K | 91.80% |
| 2016-09-30 | $61.00K | -76.54% |
| 2016-06-30 | $260.00K | -34.34% |
| 2016-03-31 | $396.00K | 44.00% |
| 2015-12-31 | $275.00K | -57.76% |
| 2015-09-30 | $651.00K | 282.94% |
| 2015-06-30 | $170.00K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | - |
Pulmatrix generated $366.00K in revenue during Q3 2024, up -76.42% compared to the previous quarter, and up 19.85% compared to the same period a year ago.
Pulmatrix Revenue Breakdown
Pulmatrix Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 |
|---|---|
| Toxicology Study Costs | $1.65M |
Latest
Pulmatrix's latest annual revenue breakdown by segment (product or service), as of Dec 20: Toxicology Study Costs (100.00%).
Pulmatrix Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 |
|---|---|
| Toxicology Study Costs | $1.65M |
Latest
Pulmatrix's latest annual revenue breakdown by geography, as of Dec 20: Toxicology Study Costs (100.00%).
Pulmatrix Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ONTX | Traws Pharma | $226.00B | $56.00K |
| CTMX | CytomX Therapeutics | $101.21M | $33.43M |
| CAPR | Capricor Therapeutics | $25.18M | $2.26B |
| PULM | Pulmatrix | $7.30M | $366.00K |
| ASMB | Assembly Biosciences | $7.16M | $6.84M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | - |
| CBIO | Gyre Therapeutics | $794.00K | - |
| SLNO | Soleno Therapeutics | - | - |
| BPTH | Bio-Path | - | - |
| MBRX | Moleculin Biotech | - | - |
| TIL | Instil Bio | - | - |
| AKTX | Akari Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| DFFN | CervoMed | - | - |